Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms
| Autor: | Hui Mei An, Meng Lv, Fu De Yang, Jing Shi, Jia Li, Zhi Ren Wang, Thoams R. Kosten, Dong Feng Zhou, Yun Long Tan, Jair C. Soares, Yue Chan Wang, Xiang Yang Zhang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Vitamin medicine.medical_specialty Side effect medicine.medical_treatment Drug Evaluation Preclinical S100 Calcium Binding Protein beta Subunit Pharmacology Tardive dyskinesia Neuroprotection Rats Sprague-Dawley Random Allocation 03 medical and health sciences Behavioral Neuroscience chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Haloperidol Animals Vitamin E Saline Movement Disorders Anti-Dyskinesia Agents Plant Extracts Brain Ginkgo biloba medicine.disease Immunohistochemistry Pathophysiology 030227 psychiatry Disease Models Animal Endocrinology chemistry Mastication Psychology Injections Intraperitoneal 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Behavioural Brain Research. 297:124-130 |
| ISSN: | 0166-4328 |
| DOI: | 10.1016/j.bbr.2015.10.004 |
| Popis: | Tardive dyskinesia (TD) is a serious side effect induced by the long-term administration of typical antipsychotics. The pathophysiology of TD remains unclear, but experimental evidence suggests that neurodegeneration caused by free radicals may play an important role in TD development. S100B is considered a potential biomarker of structural neural and glial damage. This study investigated S100B expression in TD-related brain regions and assessed the effect of antioxidants Gingko biloba leaf extract (EGb761) and vitamin E (VE) on S100B in TD rats. A total of 32 rats were randomly divided into 4 study groups: saline control (saline), haloperidol alone group (Hal), EGb761-haloperidol (EGb-Hal), and vitamin E-haloperidol (VE-Hal). Rats were treated with haloperidol intraperitoneal injections (2mg/kg/day) each day for 5 weeks. EGb761 (50mg/kg/day) and VE (20mg/kg/day) were then administered during a 5-week withdrawal period. We performed behavioral assessments and immunohistochemically analyzed S100B expression in four TD-related brain regions. Our findings demonstrated that haloperidol administration led to a progressive increase in VCMs and in S100B expression in all four brain regions. Both EGb761 and VE reversed these changes, and there were no group differences between the EGb761 and VE groups. Our results indicated that long-term administration of haloperidol may induce VCMs and increase S100B expression in TD-related brain regions, and S100B may be a significant biomarker related to TD pathophysiology. Moreover, the antioxidant capacity of EGb761 and VE coupled with the possible neuroprotective effects of S100B may account for their success in improving the symptoms of haloperidol-induced TD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect